Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 2
2003 1
2004 3
2005 1
2007 1
2008 1
2009 2
2010 2
2012 2
2013 8
2014 6
2015 3
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. van Rhee F, et al. Among authors: puchalski ta. Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17. Lancet Oncol. 2014. PMID: 25042199 Clinical Trial.
Dose selection of siltuximab for multicentric Castleman's disease.
Mayer CL, Xie L, Bandekar R, Qi M, van de Velde H, Reddy M, Qin X, Davis HM, Puchalski TA. Mayer CL, et al. Among authors: puchalski ta. Cancer Chemother Pharmacol. 2015 May;75(5):1037-45. doi: 10.1007/s00280-015-2720-0. Epub 2015 Mar 18. Cancer Chemother Pharmacol. 2015. PMID: 25784388
Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data.
Fetterly GJ, Aras U, Meholick PD, Takimoto C, Seetharam S, McIntosh T, de Bono JS, Sandhu SK, Tolcher A, Davis HM, Zhou H, Puchalski TA. Fetterly GJ, et al. Among authors: puchalski ta. J Clin Pharmacol. 2013 Oct;53(10):1020-7. doi: 10.1002/jcph.140. Epub 2013 Jul 23. J Clin Pharmacol. 2013. PMID: 23878055 Clinical Trial.
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R. Angevin E, et al. Among authors: puchalski ta. Clin Cancer Res. 2014 Apr 15;20(8):2192-204. doi: 10.1158/1078-0432.CCR-13-2200. Epub 2014 Feb 21. Clin Cancer Res. 2014. PMID: 24563479 Clinical Trial.
A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjects.
Xu C, Han C, Marini J, Ford J, Marciniak S, Lopez M Jr, Frederick B, de Vries D, Bandekar R, Davis HM, Zhou H, Puchalski TA. Xu C, et al. Among authors: puchalski ta. Clin Pharmacol Drug Dev. 2014 Jul;3(4):328-34. doi: 10.1002/cpdd.86. Epub 2013 Nov 22. Clin Pharmacol Drug Dev. 2014. PMID: 27128840 Clinical Trial.
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
Yamamoto N, Tamura T, Yamamoto N, Yamada K, Yamada Y, Nokihara H, Fujiwara Y, Takahashi T, Murakami H, Boku N, Yamazaki K, Puchalski TA, Shin E. Yamamoto N, et al. Among authors: puchalski ta. Cancer Chemother Pharmacol. 2009 Nov;64(6):1165-72. doi: 10.1007/s00280-009-0979-8. Epub 2009 Mar 24. Cancer Chemother Pharmacol. 2009. PMID: 19308410 Clinical Trial.
28 results